PFCS
PRLD icon

Pale Fire Capital SE’s Prelude Therapeutics PRLD Stock Holding History

Pale Fire Capital SE’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,481
Closed -$149K – 61
2024
Q1 		$149K Sell
31,481
-32,100
-50% -$125K 0.02% 40
2023
Q4 		$271K Buy
63,581
+32,800
+107% +$99.9K 0.04% 46
2023
Q3 		$95.1K Buy
+30,781
New +$116K 0.01% 51

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Pale Fire Capital SE's PRLD Position: Q2 2024 in Review

Pale Fire Capital SE sold out of Prelude Therapeutics (PRLD) in Q2 2024, closing a stake of 31,481 shares — an estimated $149K sold.

Pale Fire Capital SE first reported a position in PRLD in Q3 2023 and held it in 3 quarters. The position peaked at $271K in Q4 2023. 61 funds tracked by Wall St. Rank hold PRLD as of Q2 2024.

  • Pale Fire Capital SE reported no remaining Prelude Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Pale Fire Capital SE sold 31,481 Prelude Therapeutics shares in Q2 2024, an estimated $149K.
  • Pale Fire Capital SE first reported a position in Prelude Therapeutics in Q3 2023 and held it in 3 quarters.
  • Pale Fire Capital SE's Prelude Therapeutics position peaked at $271K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2024.

Based on Pale Fire Capital SE's 13F filing for Q2 2024, filed 13 Aug 2024.